Wednesday - November 5, 2025
GSK Announces Positive Pivotal Phase III Data for Next-Generation Low Carbon Version of Ventolin Metered Dose Inhaler
October 23, 2025
LONDON, England, Oct. 23 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Oct. 22, 2025:

* * *

GSK announces positive pivotal phase III data for next-generation low carbon version of Ventolin (salbutamol) metered dose inhaler

* Data confirm therapeutic equivalence and comparable safety profile for Ventolin (salbutamol) containing innovative low carbon propellant

* Approximately 300 million sal . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products